22:30 , Jun 24, 2019 |  BC Extra  |  Tools & Techniques

A new flavor of allosteric modulators: synthetic proteins

Relay co-founder and Brandeis Professor Dorothee Kern is turning to synthetic proteins rather than small molecules to drug targets at allosteric sites, a strategy she thinks will shorten the discovery process and provide added selectivity....
19:44 , Jun 5, 2019 |  BC Extra  |  Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
23:16 , Apr 16, 2019 |  BC Extra  |  Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

The bacterial AgrA inhibitor apcidin for MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus Cell culture and mouse studies suggest the S. aureus AgrA inhibitor apcidin could help treat methicillin-resistant S. aureus (MRSA) infection. In four strains of S. aureus , the natural...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2 or its downstream mediator FOXC1 could help treat AML and CML. In AML cells from...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiomyopathy Patient sample studies suggest CRISPR-mediated editing of the B isoform of LAMP2 could help treat Danon disease, a cardiomyopathy caused by a loss-of-function LAMP2 point mutations. In cardiomyocytes from patients, CRISPR-Cas9-mediated correction of...